candesartan has been researched along with eplerenone in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D | 1 |
| Omura, T; Yoshikawa, J; Yoshiyama, M | 1 |
| Hirata, Y; Hirono, Y; Kobayashi, N; Sakurada, M; Shichiri, M; Sugiyama, T; Suzuki, N; Takai, S; Yoshimoto, T | 1 |
| Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yoneda, T; Zhu, A | 1 |
| Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M | 1 |
| Homma, I; Iigaya, K; Kobayashi, Y; Minoura, Y; Onimaru, H | 1 |
| Gutiérrez Solís, E; Gutiérrez, E; Huerta, A; Morales, E; Praga, M; Segura, J | 1 |
| Frohlich, ED; Susic, D; Varagic, J | 1 |
| Ariti, CA; Collier, TJ; Pocock, SJ; Wang, D | 1 |
| Cheng, Y; Demura, M; Karashima, S; Takata, H; Takeda, Y; Yagi, K; Yamagishi, M; Yoneda, T; Zhu, A | 1 |
| Gabor, A; Leenen, FH | 1 |
| Amann, K; Brand, S; Mandel, P; Schupp, N; Zimnol, A | 1 |
| Goto, M; Hasebe, N; Takahashi, F; Wada, Y | 1 |
2 review(s) available for candesartan and eplerenone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Eplerenone; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Rats; Spironolactone; Tetrazoles; Ventricular Dysfunction, Left; Ventricular Remodeling | 2004 |
2 trial(s) available for candesartan and eplerenone
| Article | Year |
|---|---|
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Eplerenone; Female; Humans; Lisinopril; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Obesity; Prospective Studies; Proteinuria; Spironolactone; Tetrazoles | 2009 |
10 other study(ies) available for candesartan and eplerenone
| Article | Year |
|---|---|
Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Vessels; Cyclic N-Oxides; Eplerenone; Gene Expression Regulation; Hypertension; Inflammation Mediators; Male; Models, Biological; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Spin Labels; Spironolactone; Tetrazoles | 2007 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinogen; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomegaly; Endothelium, Vascular; Eplerenone; Fibrosis; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Spironolactone; Tetrazoles | 2007 |
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation | 2008 |
Electrophysiological responses of sympathetic preganglionic neurons to ANG II and aldosterone.
Topics: Aldosterone; Anesthetics, Local; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Fibers, Preganglionic; Benzimidazoles; Biphenyl Compounds; Eplerenone; Excitatory Postsynaptic Potentials; Female; In Vitro Techniques; Male; Mineralocorticoid Receptor Antagonists; Patch-Clamp Techniques; Presynaptic Terminals; Rats; Rats, Wistar; Spironolactone; Synaptic Transmission; Tetrazoles; Tetrodotoxin; Time Factors | 2009 |
Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiomyopathies; Cardiovascular System; Eplerenone; Hypertension; Hypertrophy; Kidney; Male; Mineralocorticoid Receptor Antagonists; Quinapril; Rats; Rats, Inbred SHR; Receptors, Mineralocorticoid; Regional Blood Flow; Renin-Angiotensin System; Sodium Chloride, Dietary; Spironolactone; Tetrahydroisoquinolines; Tetrazoles; Ventricular Dysfunction, Left | 2010 |
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazoles; Biphenyl Compounds; Cardiac Catheterization; Cardiovascular Diseases; Clinical Trials as Topic; Endpoint Determination; Eplerenone; Heart Failure; Hospitalization; Humans; Matched-Pair Analysis; Mineralocorticoid Receptor Antagonists; Proportional Hazards Models; Risk Factors; Spironolactone; Tetrazoles | 2012 |
Protective effects of mineralocorticoid receptor blockade against neuropathy in experimental diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Eplerenone; Male; Mineralocorticoid Receptor Antagonists; NF-kappa B; Peripheral Nerves; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Tetrazoles | 2012 |
Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Eplerenone; Glutamic Acid; Heart Rate; Hypertension; Infusions, Intravenous; Infusions, Intraventricular; Kynurenic Acid; Male; Mineralocorticoid Receptor Antagonists; Paraventricular Hypothalamic Nucleus; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Glutamate; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Tetrazoles | 2013 |
Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclic N-Oxides; Deoxyguanosine; DNA Damage; DNA Repair; Enzyme Activation; Eplerenone; Guanosine; Heart; Hypertension; Kidney; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System; Spin Labels; Spironolactone; Tetrazoles | 2014 |
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Creatinine; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hypertension, Malignant; Male; Nifedipine; Nitroglycerin; Obesity; Renal Insufficiency; Spironolactone; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2015 |